# NIH Reporter #11384975

Investigating immunomodulation of p53 mutant ovarian cancer

**Recipient:** Thomas Jefferson University

**Award Amount:** $51,477.00
**Ceiling:** $51,477.00

**Awarded:** August 06, 2026

**Identifier:** 11384975

This NIH-funded project at Thomas Jefferson University investigates how MDM2 degradation affects immune signaling in p53 mutant ovarian cancer, aiming to improve anti-tumor immunity and develop new treatments.

### Description

The project focuses on the molecular mechanisms by which MDM2 degradation triggers immune signaling pathways in high grade serous ovarian cancer (HGSOC). It aims to investigate effects on the tumor microenvironment and enhance anti-tumor immunity. The project involves developing and testing a PROTAC to target MDM2 for degradation, with potential translational applications in ovarian cancer treatment. The study will interface with clinicians and scientists to foster training in translational cancer research.

[View original record](https://reporter.nih.gov/search/IgE1H2ioLUOz0qmA4MDg0Q/project-details/11384975)